Antimicrobial prophylaxis protocol based on rectal swab culture before prostate biopsy to prevent infectious complications: a prospective randomized comparative study.
Antibiotic prophylaxis
Enterobacterales
Fluoroquinolone resistance
Infectious complication
Prostate biopsy
Rectal swab
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
18
10
2023
accepted:
16
02
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
To evaluate the benefit of targeted antibiotic prophylaxis (TAP) based on rectal swab culture in comparison with standard empiric antimicrobial prophylaxis in patients undergoing transrectal ultrasound-guided needle biopsy of the prostate (TRUS-BP), as well as to assess rate of fecal carriage of Fluoroquinolone-resistant Enterobacterales FQRE. We prospectively analyzed data that randomized 157 patients within two groups: (G1) TAP according to rectal swab performed 10 days before PB; (G2): empirical antibiotic prophylaxis with ciprofloxacin. Prevalence of FQRE digestive carriage and risk factors were investigated. Incidence of infectious complications after (TRUS-BP) in each group was compared. G2 included 80 patients versus 77 in G1. There was no difference between the two groups regarding age, diabetes, prostate volume, PSA, number of biopsy cores, and risk factors for FQRE. In G2, the prevalence of FQRE digestive carriage was 56.3% all related to E. coli species. In the case of digestive carriage of FQRE, TAP according to the rectal swab culture with third-generation cephalosporins was performed in 73.3%. Patients with FQRE had history of FQ use within the last 6 months in 17.8% (p = 0.03). Rate of febrile urinary tract infection after PB was 13% in G1 and 3.8% in G2 (p = 0.02). Incidence of FQ resistance in the intestinal flora of our local population was prevalent. Risk factor for resistance was the use of FQ within the last 6 months. TAP adapted to rectal swab, mainly with third-generation cephalosporins, significantly reduced the rate of infectious complications after (TRUS-BP).
Identifiants
pubmed: 38448785
doi: 10.1007/s11255-024-03998-7
pii: 10.1007/s11255-024-03998-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH (2002) Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60(5):826–830. https://doi.org/10.1016/s0090-4295(02)01958-1
doi: 10.1016/s0090-4295(02)01958-1
pubmed: 12429309
Bootsma AM, Laguna Pes MP, Geerlings SE, Goossens A (2008) Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 54(6):1270–1286. https://doi.org/10.1016/j.eururo.2008.03.033
doi: 10.1016/j.eururo.2008.03.033
pubmed: 18423974
Akduman B, Akduman D, Tokgöz H, Erol B, Türker T, Ayoğlu F, Mungan NA (2011) Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 78(2):250–255. https://doi.org/10.1016/j.urology.2011.02.065
doi: 10.1016/j.urology.2011.02.065
pubmed: 21705048
Ozden E, Bostanci Y, Yakupoglu KY, Akdeniz E, Yilmaz AF, Tulek N, Sarikaya S (2009) Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 74(1):119–123. https://doi.org/10.1016/j.urology.2008.12.067
doi: 10.1016/j.urology.2008.12.067
pubmed: 19464043
Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C, Rao GG, Dash A, Park S, Patel N, Woo J, McDonald M, Nseyo U, Banapour P, Unterberg S, Ahlering TE, Van Poppel H, Sakamoto K, Fierer J, Black PC (2014) Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 192(6):1673–1678. https://doi.org/10.1016/j.juro.2014.06.005
doi: 10.1016/j.juro.2014.06.005
pubmed: 24928266
Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D, Machan L, Black P (2013) Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int 111(6):946–953. https://doi.org/10.1111/j.1464-410X.2012.11637.x
doi: 10.1111/j.1464-410X.2012.11637.x
pubmed: 23464844
Wagenlehner FM, Pilatz A, Waliszewski P, Weidner W, Johansen TE (2014) Reducing infection rates after prostate biopsy. Nat Rev Urol 11(2):80–86. https://doi.org/10.1038/nrurol.2013.322
doi: 10.1038/nrurol.2013.322
pubmed: 24418806
Summers SJ, Patel DP, Hamilton BD, Presson AP, Fisher MA, Lowrance WT, Southwick AW (2015) An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy. World J Urol 33(12):2001–2007. https://doi.org/10.1007/s00345-015-1571-y
doi: 10.1007/s00345-015-1571-y
pubmed: 25935330
Holmbom M, Forsberg J, Fredrikson M, Nilsson M, Nilsson LE, Hanberger H, Hällgren A (2023) Fluoroquinolone-resistant Escherichia coli among the rectal flora is the predominant risk factor for severe infection after transrectal ultrasound-guided prostate biopsy: a prospective observational study. Scand J Urol 8(58):32–37. https://doi.org/10.2340/sju.v58.11920
doi: 10.2340/sju.v58.11920
Benli E, Yuce A, Cirakoglu A, Yazici I, Kadim N, Nalbant I (2022) Effect of targeted prophylaxis with rectal swab on complications after prostate biopsy: prospective randomized study. Ir J Med Sci 191(3):1147–1152. https://doi.org/10.1007/s11845-021-02723-y
doi: 10.1007/s11845-021-02723-y
pubmed: 34304346
Naber KG, Sörgel F (2003) Antibiotic therapy–rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 35(5):331–335
doi: 10.1111/j.1439-0272.2003.tb00868.x
pubmed: 14535866
Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM, Whalen E, Kowalsky SF (1998) Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 52(4):552–558. https://doi.org/10.1016/s0090-4295(98)00296-9
doi: 10.1016/s0090-4295(98)00296-9
pubmed: 9763070
G. Bonkat (Chair), R. Bartoletti, F. Bruyère, T. Cai, S.E. Geerlings, B. Köves, S. Schubert, F. Wagenlehner, Guidelines Associates: T. Mezei, A. Pilatz, B. Pradere, R. Veeratterapillay . EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam the Netherlands 2020. ISBN 978–94–92671–07–3.
Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS (2011) Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 77(5):1035–1041. https://doi.org/10.1016/j.urology.2010.12.067
doi: 10.1016/j.urology.2010.12.067
pubmed: 21420152
Wagenlehner F, Stöwer-Hoffmann J, Schneider-Brachert W, Naber KG, Lehn N (2000) Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology. Int J Antimicrob Agents 15(3):207–211. https://doi.org/10.1016/s0924-8579(00)00182-5
doi: 10.1016/s0924-8579(00)00182-5
pubmed: 10926443
Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, Murphy AB, Dielubanza E, Schaeffer AJ (2012) Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 187(4):1275–1279. https://doi.org/10.1016/j.juro.2011.11.115
doi: 10.1016/j.juro.2011.11.115
pubmed: 22341272
Duplessis CA, Bavaro M, Simons MP, Marguet C, Santomauro M, Auge B, Collard DA, Fierer J, Lesperance J (2012) Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 79(3):556–561. https://doi.org/10.1016/j.urology.2011.09.057
doi: 10.1016/j.urology.2011.09.057
pubmed: 22386395
Liss MA, Chang A, Santos R, Nakama-Peeples A, Peterson EM, Osann K, Billimek J, Szabo RJ, Dash A (2011) Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 185(4):1283–1288. https://doi.org/10.1016/j.juro.2010.11.088
doi: 10.1016/j.juro.2010.11.088
pubmed: 21334021
pmcid: 4063558
Suwantarat N, Dumford DM 3rd, Ponce-Terashima R, Kundrapu S, Zabarsky TF, Zhu H, Donskey CJ (2013) Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy. Infect Control Hosp Epidemiol 34(9):973–976. https://doi.org/10.1086/671734
doi: 10.1086/671734
pubmed: 23917913
Dai J, Leone A, Mermel L, Hwang K, Pareek G, Schiff S, Golijanin D, Renzulli JF 2nd (2015) Rectal swab culture-directed antimicrobial prophylaxis for prostate biopsy and risk of postprocedure infection: a cohort study. Urology 85(1):8–14. https://doi.org/10.1016/j.urology.2014.09.035
doi: 10.1016/j.urology.2014.09.035
pubmed: 25458193
Tsu JH, Ma WK, Chan WK, Lam BH, To KC, To WK, Ng TK, Liu PL, Cheung FK, Yiu MK (2015) Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum β-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy. Urology 85(1):15–21. https://doi.org/10.1016/j.urology.2014.07.078
doi: 10.1016/j.urology.2014.07.078
pubmed: 25444632
Piekarska K, Zacharczuk K, Wołkowicz T, Mokrzyś M, Wolaniuk N, Nowakowska M, Szempliński S, Dobruch J, Gierczyński R (2021) The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis. Ann Clin Microbiol Antimicrob 20(1):81. https://doi.org/10.1186/s12941-021-00487-y
doi: 10.1186/s12941-021-00487-y
pubmed: 34876123
pmcid: 8650336
Tekdoğan Ü, Tuncel A, Eroğlu M, Ünsal A, Atan A, Balbay MD (2006) The efficiency of prophylactic antibiotic treatment in patients without risk factor who underwent transrectal. Türk Üroloji Dergisi 32(2):261–267
Wang H, Zhou X, Chen S, Zhu C, Yu X (2004) Investigation of infection risk and the value of antibiotic prophylaxis during transrectal biopsy of the prostate by endotoxin determination. Zhonghua Nan Ke Xue 10(7):496–498
pubmed: 15354517
Kehinde EO, Al-Maghrebi M, Sheikh M, Anim JT (2013) Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. J Urol 189(3):911–915. https://doi.org/10.1016/j.juro.2012.08.237
doi: 10.1016/j.juro.2012.08.237
pubmed: 23009873
Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y (2013) Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 189(2):535–540. https://doi.org/10.1016/j.juro.2012.08.194
doi: 10.1016/j.juro.2012.08.194
pubmed: 22982426
Song W, Choo SH, Sung HH, Han DH, Jeong BC, Seo SI, Jeon SS, Lee KS, Lee SW, Lee HM, Choi HY, Jeon HG (2014) Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy. Urology 84(5):1001–1007. https://doi.org/10.1016/j.urology.2014.06.052
doi: 10.1016/j.urology.2014.06.052
pubmed: 25443894
Tukenmez Tigen E, Tandogdu Z, Ergonul O, Altinkanat G, Gunaydin B, Ozgen M, Sariguzel N, Erturk Sengel B, Odabasi Z, Cek M, Tokuc R, Turkeri L, Mulazimoglu L, Korten V (2014) Outcomes of fecal carriage of extended-spectrum β-lactamase after transrectal ultrasound-guided biopsy of the prostate. Urology 84(5):1008–1015. https://doi.org/10.1016/j.urology.2014.04.060
doi: 10.1016/j.urology.2014.04.060
pubmed: 25239255
Tops SCM, Kolwijck E, Koldewijn EL, Somford DM, Delaere FJM, van Leeuwen MA, Breeuwsma AJ, de Vocht TF, Broos HJHP, Schipper RA, Steffens MG, Teerenstra S, Wegdam-Blans MCA, de Brauwer E, van den Bijllaardt W, Leenders ACAP, Sedelaar JPM, Wertheim HFL (2023) Rectal culture-based versus empirical antibiotic prophylaxis to prevent infectious complications in men undergoing transrectal prostate biopsy: a randomized. Nonblinded Multicent Trial Clin Infect Dis 76(7):1188–1196. https://doi.org/10.1093/cid/ciac913
doi: 10.1093/cid/ciac913
Minamida S, Satoh T, Tabata K, Kimura M, Tsumura H, Kurosaka S, Matsumoto K, Fujita T, Iwamura M, Baba S (2011) Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology 78(6):1235–1239. https://doi.org/10.1016/j.urology.2011.07.1392
doi: 10.1016/j.urology.2011.07.1392
pubmed: 21908030
Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy–should we reassess our practices for antibiotic prophylaxis. Clin Microbiol Infect 18(6):575–581. https://doi.org/10.1111/j.1469-0691.2011.03638.x
doi: 10.1111/j.1469-0691.2011.03638.x
pubmed: 21958149